Physician profile
Derek Kent
NPI 1548847833
$1,437.16
in general payments reported to CMS, 2019-2025
21 companies · $1,011 in 2025
The $1,011 reported for 2025 was more than what 86% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $426 · 2025: $1,011.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,373 · Education: $64.54.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,372.62 |
| Education | $64.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $272.66 | 2024-2025 | Fanapt |
| Novo Nordisk INC | $213.52 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $184.76 | 2024-2025 | |
| Axsome Therapeutics, INC. | $92.99 | 2024-2025 | Auvelity |
| Viatris Specialty LLC | $82.43 | 2025 | Yupelri |
| Amgen INC. | $81.28 | 2025 | Otezla, Repatha |
| Lilly USA, LLC | $72.87 | 2025 | Mounjaro, Zepbound |
| Phathom Pharmaceuticals, INC. | $54.16 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $50.98 | 2024-2025 | Farxiga, Airsupra |
| Teva Pharmaceuticals USA, INC. | $48.30 | 2024-2025 | Austedo Xr, Austedo Xr, Ajovy |
| Insulet Corporation | $43.55 | 2025 | Omnipod |
| Corcept Therapeutics | $43.53 | 2025 | Korlym |
| Regeneron Healthcare Solutions, INC. | $34.68 | 2025 | Dupixent |
| Supernus Pharmaceuticals, INC. | $31.16 | 2025 | Qelbree |
| Pfizer INC. | $28.22 | 2024-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alkermes, INC. | $20.48 | 2025 | Vivitrol |
| Linus Health, INC. | $19.47 | 2024 | Core Cognitive Evaluation |
| Shield Therapeutics INC | $17.61 | 2025 | |
| Boston Scientific Corporation | $15.28 | 2025 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.74 | 2024 | Trulance, Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.49 | 2025 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Derek Kent listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.